HENGRUI THERAPEUTICS, INC.
  • Home
  • Who We Are
  • R&D
  • News
    • News and Buzz
    • Scientific and Medical Releases
  • Partners
  • Careers
  • Contact
  • News and Buzz

COMMITMENT...MATTERS

NEWS & BUZZ ABOUT HENGRUI

​6/24/2020
Hengrui signed agreement with Thermo Fisher Scientific on companion diagnostic to identify NSCLC patients for Pyrotinib treatment
​11/19/2019
​
Hengrui announced the initiation of a phase 3 pivotal clinical trial to evaluate the safety and efficacy of pyrotinib on HER2 exon 20 mutated NSCLC patients in the second-line settings.
4/19/2019
Hengrui Therapeutics initiated a global Phase 3 study to investigate the efficacy and safety of camrelizumab and rivoceranib (apatinib) in first line HCC patients.
6/1/2018         
Hengrui Medicine places in Forbes's list of top 100 world's most innovative companies
5/17/2018
Hengrui Medicine featured by Financial Times under "China Pharma Boosts Generics Exports to US"
​4/17/2018
​
Hengrui Medicine featured in Bloomberg Opinion tilted "4,000,000 Reasons to Back China Biotech."
​1/8/2018
TG Therapeutics and Hengrui Medicine announce global license agreement for development and commercialization of novel BTK inhibitor program for the treatment of hematologic malignancies
1/5/2018
Hengrui Medicine and Arcutis partner to development novel immune-mediated dermatology therapy using SHR0302, a potentially best-in-class JAK inhibitor
6/27/2016
Hengrui Medicine and an undisclosed US investment firm invest $100 million on Hengrui Therapeutics Inc to advance clinical trials in Hengrui Therapeutics' pharmaceutical research and development 
5/3/2016
Hengrui Medicine signs a 3-year pact with the MD Anderson Cancer Center at the University of Texas, Houston with an immuno-oncology focus on combination therapies, personalized medicine and new treatment opportunities 
4/25/2016
Hengrui Medicine collaborates with Albert Einstein College of Medicine to advance cancer research and drug discovery
9/3/2015
​
Hengrui Medicine became the first Chinese firm to license a drug candidate to a U.S. biotech: Incyte agreed to pay $795 million in total potential up and milestone payments for ex-China rights to camrelizumab, a PD-1 antibody in phase II clinical trials in China ​
7/30/2015
Hengrui Medicine licenses Rolapitant, an NK-1 receptor antagonist, from Tesaro
​7/15/2015
Hengrui Medicine invests ¥850 million (US$137 million) into the building of a biologics manufacturing plant that follows FDA and EMEA standards with expectations of entering markets outside of China ​​​

HOME


​

WHO WE ARE
Our Team

R&D
HTI Pipeline Overview
R&D Sites​
​

NEWS
News and Buzz
Scientific and Medical Releases

PARTNERS
Clinical Trial Partners
Academic Partners
Corporate Alliances

CAREERS
Job Opportunities

CONTACT
506 Carnegie Center, ​Suite 102
Princeton, NJ 08540
609.423.2155

​info@hengruitx.com

​

Picture
Copyright © 2018
  • Home
  • Who We Are
  • R&D
  • News
    • News and Buzz
    • Scientific and Medical Releases
  • Partners
  • Careers
  • Contact
  • News and Buzz